Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

This study is testing a two-step treatment approach for people with multiple myeloma (a type of blood cancer) that has come back or stopped responding to prior treatments. Patients first receive a drug called talquetamab (a bispecific antibody), and then transition to a personalized cell therapy called ciltacabtagene autoleucel (cilta-cel, a CAR-T therapy). The goal is to see if using talquetamab as a bridge helps make the CAR-T therapy more effective. **You may be eligible if...** - You are over 18 years old - You have confirmed relapsed or worsening multiple myeloma - You have received at least one prior treatment that included a proteasome inhibitor, an anti-CD38 antibody, and an immunomodulatory drug - Your doctor has determined you are eligible to receive both talquetamab and cilta-cel per current FDA guidelines - Your heart, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have previously received CAR-T cell therapy, a bispecific antibody, or talquetamab - You have ever received a treatment targeting BCMA or GPRC5D - You have had an allogeneic (donor) stem cell transplant - You have active cancer spread to the brain or spinal fluid - You have severe heart disease (e.g., very low heart pumping function, recent heart attack) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.